Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

One Test Could Add Significant Value At Chembio

Chembio (NASDAQ:CEMI) is a diagnostic company with a focus on developing and marketing point of care tests. Since 2008, the company's revenues have grown significantly as it has penetrated international markets, developed new technology and worked with its U.S. partner, Alere (NYSE:ALR), to gain share.

(click to enlarge)

Despite the impressive run up in sales, stock performance has been disappointing over the past year. Up to March of this year, it looked as if the company's shares were on a roll (with the rest of the market). Then two events happened. First, the company reported its fourth quarter 2012 results on March 7. Despite sales in the quarter being 18% higher than in any other quarter...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details